Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

ClinicalTrials.gov ID: NCT00735267

Public ClinicalTrials.gov record NCT00735267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.

Study identification

NCT ID
NCT00735267
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
468 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2008 (Type not available)
Primary completion
Apr 2009 (Actual)
Completion
Apr 2009 (Actual)
Last update posted
Nov 16, 2012

2008 – 2009

United States locations

U.S. sites
93
U.S. states
32
U.S. cities
82
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35226 —
Pfizer Investigational Site Litchfield Park Arizona 85340 —
Pfizer Investigational Site Arcadia California 91007-3462 —
Pfizer Investigational Site Beverly Hills California 90210 —
Pfizer Investigational Site Costa Mesa California 92626 —
Pfizer Investigational Site Costa Mesa California 92627 —
Pfizer Investigational Site Encino California 91316 —
Pfizer Investigational Site Escondido California 92025 —
Pfizer Investigational Site Murrieta California 92562 —
Pfizer Investigational Site National City California 91950 —
Pfizer Investigational Site Newport Beach California 92660-2452 —
Pfizer Investigational Site Orange California 92868 —
Pfizer Investigational Site Pasadena California 91106 —
Pfizer Investigational Site Redlands California 92374 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site San Diego California 92108 —
Pfizer Investigational Site Sherman Oaks California 91403 —
Pfizer Investigational Site Temecula California 92591 —
Pfizer Investigational Site Upland California 91786 —
Pfizer Investigational Site Wildomar California 92595 —
Pfizer Investigational Site Denver Colorado 80239 —
Pfizer Investigational Site Hamden Connecticut 06518 —
Pfizer Investigational Site Norwich Connecticut 06360 —
Pfizer Investigational Site Altamonte Springs Florida 32701 —
Pfizer Investigational Site Fort Myers Florida 33912 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Maitland Florida 32751 —
Pfizer Investigational Site Miami Florida 33126 —
Pfizer Investigational Site Miami Florida 33143 —
Pfizer Investigational Site Orange City Florida 32763 —
Pfizer Investigational Site Orlando Florida 32806 —
Pfizer Investigational Site South Miami Florida 33143 —
Pfizer Investigational Site West Palm Beach Florida 33407 —
Pfizer Investigational Site Atlanta Georgia 30308 —
Pfizer Investigational Site Atlanta Georgia 30328 —
Pfizer Investigational Site Marietta Georgia 30060 —
Pfizer Investigational Site Libertyville Illinois 60048 —
Pfizer Investigational Site Naperville Illinois 60563 —
Pfizer Investigational Site Park Ridge Illinois 60068 —
Pfizer Investigational Site Greenwood Indiana 46143 —
Pfizer Investigational Site Terre Haute Indiana 47802 —
Pfizer Investigational Site Overland Park Kansas 66212 —
Pfizer Investigational Site Prairie Village Kansas 66206 —
Pfizer Investigational Site Wichita Kansas 67207 —
Pfizer Investigational Site Owensboro Kentucky 42301 —
Pfizer Investigational Site Lake Charles Louisiana 70601 —
Pfizer Investigational Site Baltimore Maryland 21208 —
Pfizer Investigational Site Belmont Massachusetts 02478 —
Pfizer Investigational Site Boston Massachusetts 02135 —
Pfizer Investigational Site Fall River Massachusetts 02721 —
Pfizer Investigational Site Haverhill Massachusetts 01830 —
Pfizer Investigational Site Pittsfield Massachusetts 01201 —
Pfizer Investigational Site Omaha Nebraska 68131 —
Pfizer Investigational Site Las Vegas Nevada 89146 —
Pfizer Investigational Site Nashua New Hampshire 03060 —
Pfizer Investigational Site Albuquerque New Mexico 87109 —
Pfizer Investigational Site Brooklyn New York 11235 —
Pfizer Investigational Site New York New York 10023 —
Pfizer Investigational Site New York New York 10024 —
Pfizer Investigational Site New York New York 10128-1708 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site The Bronx New York 10467 —
Pfizer Investigational Site Raleigh North Carolina 27607 —
Pfizer Investigational Site Columbus Ohio 43210 —
Pfizer Investigational Site Dayton Ohio 45408 —
Pfizer Investigational Site Toledo Ohio 43609 —
Pfizer Investigational Site Toledo Ohio 43623 —
Pfizer Investigational Site Bethany Oklahoma 73008 —
Pfizer Investigational Site Oklahoma City Oklahoma 73103 —
Pfizer Investigational Site Oklahoma City Oklahoma 73116 —
Pfizer Investigational Site Portland Oregon 97210 —
Pfizer Investigational Site Salem Oregon 97301 —
Pfizer Investigational Site Allentown Pennsylvania 18104 —
Pfizer Investigational Site Media Pennsylvania 19063 —
Pfizer Investigational Site Norristown Pennsylvania 19401 —
Pfizer Investigational Site Philadelphia Pennsylvania 19139 —
Pfizer Investigational Site Lincoln Rhode Island 02865 —
Pfizer Investigational Site Columbia South Carolina 29201 —
Pfizer Investigational Site Memphis Tennessee 38119 —
Pfizer Investigational Site Memphis Tennessee 38134 —
Pfizer Investigational Site Austin Texas 78756 —
Pfizer Investigational Site Dallas Texas 75230 —
Pfizer Investigational Site Dallas Texas 75231 —
Pfizer Investigational Site DeSoto Texas 75115 —
Pfizer Investigational Site Houston Texas 77008 —
Pfizer Investigational Site Houston Texas 77074 —
Pfizer Investigational Site Lake Jackson Texas 77566 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Woodstock Vermont 05091 —
Pfizer Investigational Site Charlottesville Virginia 22903 —
Pfizer Investigational Site Seattle Washington 98104 —
Pfizer Investigational Site Middleton Wisconsin 53562 —
Pfizer Investigational Site Waukesha Wisconsin 53188-1660 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00735267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2012 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00735267 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →